CP-R3 is a triple receptor agonist currently being investigated for metabolic regulation, energy expenditure, and body composition research. It activates GLP-1, GIP, and glucagon receptors simultaneously, making it one of the most advanced compounds currently being studied.
Metabolic Research
GLP-1 • GIP • GCGR
Clinical & Preclinical
Weight Management
CP-R3 is a proprietary designation used by ChoicePeps for a research compound corresponding to retatrutide, a next-generation triple receptor agonist that simultaneously activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-pathway approach has generated significant scientific interest because it combines mechanisms associated with appetite regulation, glucose homeostasis, and energy expenditure into a single investigational molecule.
Unlike earlier dual agonists that target only GLP-1 and GIP receptors, CP-R3 incorporates glucagon receptor activity, allowing researchers to investigate its potential effects on metabolic flexibility, body composition, and overall energy balance. Preclinical and clinical studies have demonstrated substantial reductions in body weight while also improving multiple markers of metabolic health, making CP-R3 one of the most extensively studied investigational metabolic peptides currently under development.
Current research continues to explore CP-R3’s pharmacology, receptor signaling, safety profile, and potential applications across obesity, metabolic disease, and related areas of biomedical research. As with all compounds featured in the ChoicePeps Research Library, CP-R3 is presented for educational and scientific reference purposes only.
Comprehensive reviews discuss the scientific rationale behind combining GLP-1, GIP, and glucagon receptor agonism to maximize metabolic regulation.
Review articles describe triple agonists as one of the most promising emerging therapeutic approaches for obesity and metabolic disease research.
Phase II clinical trial demonstrating significant weight reduction and improvements in metabolic biomarkers with triple receptor agonism.
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise : a double-blind, randomised, phase 3 trial.
Current preclinical and clinical research is investigating CP-R3 across several key areas of metabolic science.
CP-R3 is ChoicePeps’ proprietary designation for a triple receptor agonist currently being investigated for its effects on body weight, metabolic regulation, and energy balance. It activates the GLP-1, GIP, and glucagon receptors simultaneously, distinguishing it from earlier dual agonists.
Unlike GLP-1 receptor agonists alone or dual GLP-1/GIP agonists, CP-R3 also activates the glucagon receptor. Researchers believe this additional pathway may contribute to increased energy expenditure and enhanced metabolic effects while complementing appetite regulation.
Triple receptor agonists are being investigated because they target multiple metabolic pathways simultaneously. Current research suggests this approach may improve body weight reduction, glucose regulation, insulin sensitivity, and overall metabolic health more effectively than activating a single pathway alone.
CP-R3 has been evaluated in preclinical studies as well as Phase II and Phase III clinical trials. Published research has reported significant reductions in body weight along with improvements in several cardiometabolic biomarkers, although research is ongoing.
CP-R3 activates three key receptors involved in metabolic regulation:
No. It remains an investigational compound and is not currently approved by the U.S. Food and Drug Administration (FDA). Research is ongoing to evaluate its long-term safety and efficacy.
The information presented in the ChoicePeps Research Library is provided solely for educational and informational purposes. Content is compiled from publicly available scientific literature and is intended to summarize current areas of research involving investigational compounds.
The material presented on this page has not been evaluated by the U.S. Food and Drug Administration (FDA) and should not be interpreted as medical advice, treatment recommendations, or evidence of clinical efficacy. Scientific understanding continues to evolve as additional laboratory and clinical research becomes available.
ChoicePeps does not make claims regarding the diagnosis, treatment, cure, or prevention of any disease. Visitors are encouraged to consult original peer-reviewed publications when reviewing scientific findings.
